







an Open Access Journal by MDPI

Controlled Clinical Evaluation of Veterinary Vaccines

Guest Editors:

Prof. Dr. Eyal Klement

The Koret School of Veterinary Medicine, The Robert H. Smith Faculty of Agriculture, Food and Environment, The Hebrew University of Jerusalem, PO Box 12, Rehovot 76100, Israel

Prof. Nahum Shpigel

The Koret School of Veterinary Medicine, The Robert H. Smith Faculty of Agriculture, Food and Environment, The Hebrew University of Jerusalem, PO Box 12, Rehovot 76100, Israel

Deadline for manuscript submissions:

closed (31 March 2021)

Message from the Guest Editors

Dear Colleagues,

Infectious diseases in animals have been intertwined throughout human history, thanks to over 10 millennia of domestication and the development of farming societies. During these periods, microbial pathogens have constituted a constant threat to animal and human health and welfare. Vaccines are widely used to control many infectious diseases of veterinary importance.

We welcome the submission of manuscripts describing the results of studies designed to collect such information. Such data can be collected in challenge studies, clinically controlled efficacy field studies, outbreak investigations or controlled field observational studies. However, such studies should not be limited only to such outcomes and should include an evaluation of the clinical efficacy or effectiveness and/or controlled clinical evaluation of adverse effects caused by the vaccine. We expect the information gathered in this Special Issue to support the decision making of all stakeholders interested in the control of veterinary infectious diseases.

Prof. Dr. Eyal Klement Prof. Nahum Shpigel *Guest Editors*







IMPACT FACTOR 7.8





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine, University of Georgia, Athens, GA 30602-7387, USA

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Author Benefits

Open Access: free for readers, with <u>article processing charges (APC)</u> paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Immunology) / CiteScore - Q1 (Pharmacology (medical))

Contact Us